Annual report pursuant to Section 13 and 15(d)

Restatement of Financial Statements - Additional information (Details)

v3.22.2
Restatement of Financial Statements - Additional information (Details) - USD ($)
 1 Months Ended 12 Months Ended
Dec. 18, 2020
Oct. 31, 2021
Mar. 31, 2021
Dec. 31, 2021
Dec. 31, 2020
Error Corrections and Prior Period Adjustments Restatement [Line Items]          
In-process R&D       $ 10,599,000 $ 9,536,000
Goodwill       0 3,631,212
Decrease in contingent consideration       (475,956) (1,230,170)
Goodwill Impairment       4,037,811 0
Panoptes          
Error Corrections and Prior Period Adjustments Restatement [Line Items]          
Contingent consideration liability         1,353,000
Contingent consideration current liability payable         212,000
Increase in additional paid-in capital $ 1,500,000        
Increase decrease in goodwill 147,000        
Decrease in contingent consideration $ 1,353,000   $ 474,000    
Jade acquisition          
Error Corrections and Prior Period Adjustments Restatement [Line Items]          
Contingent consideration liability       580,000 480,000
Decrease in contingent consideration       100,000  
Jade acquisition | 2020 Restatement Adjustment          
Error Corrections and Prior Period Adjustments Restatement [Line Items]          
Decrease in contingent consideration         $ 100,000
Jade acquisition | 2021 Restatement Adjustment          
Error Corrections and Prior Period Adjustments Restatement [Line Items]          
Contingent Consideration Expense / (Recovery)       $ 1,230,000  
Bayon acquisition          
Error Corrections and Prior Period Adjustments Restatement [Line Items]          
In-process R&D   $ 302,000      
Deferred tax liability   76,000.000      
Increase decrease in goodwill   607,000      
Decrease in contingent consideration   381,000      
Goodwill Impairment   $ 407,000